Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AIM ImmunoTech (AIM) Capital Expenditures (2018 - 2023)

Historic Capital Expenditures for ImmunoTech (AIM) over the last 9 years, with Q3 2023 value amounting to $1000.0.

  • ImmunoTech's Capital Expenditures changed N/A to $1000.0 in Q3 2023 from the same period last year, while for Dec 2024 it was $10000.0, marking a year-over-year change of. This contributed to the annual value of $18000.0 for FY2024, which is N/A changed from last year.
  • Latest data reveals that ImmunoTech reported Capital Expenditures of $1000.0 as of Q3 2023.
  • ImmunoTech's Capital Expenditures' 5-year high stood at $49000.0 during Q2 2019, with a 5-year trough of $1000.0 in Q3 2023.
  • In the last 3 years, ImmunoTech's Capital Expenditures had a median value of $6000.0 in 2019 and averaged $13000.0.
  • Its Capital Expenditures has fluctuated over the past 5 years, first soared by 10229.36% in 2019, then plummeted by 9591.84% in 2020.
  • Over the past 3 years, ImmunoTech's Capital Expenditures (Quarter) stood at $5000.0 in 2019, then tumbled by 60.0% to $2000.0 in 2020, then tumbled by 50.0% to $1000.0 in 2023.
  • Its Capital Expenditures stands at $1000.0 for Q3 2023, versus $2000.0 for Q2 2020 and $7000.0 for Q1 2020.